Salivary duct carcinoma (SDC) is aggressive with limited therapeutic options. A subset of
SDC display human epidermal growth factor receptor 2 (HER2) protein overexpression by …

Salivary duct carcinoma (SDC) is an aggressive salivary gland malignancy with poor
survival. Approximately 30% SDC harbor HER2 amplification and response to trastuzumab …

Background HER2 aberrations in salivary gland carcinomas (SGC) as well as benefit of
HER2 directed therapy have been reported in small studies. However, reliable estimates of …

Herein we report two cases of advanced and/or metastatic salivary duct carcinoma that
relapsed after standard first‑line chemotherapy. As overexpression of human epidermal …

Background Salivary ductal carcinoma and carcinoma ex pleomorphic adenoma (CEPA) are
aggressive salivary gland cancers with poor prognosis. The standard of care is resection …

Background Salivary ductal carcinoma is a rare cancer with poor prognosis and limited
treatment options. Human epidermal receptor 2 (HER2)‐directed treatment has been …

Salivary duct carcinoma (SDC) is one of the most aggressive salivary gland tumors, and
prognosis remains poor for most patients. The aim of this study was to investigate the …

Salivary duct carcinoma (SDC) is an aggressive carcinoma with poor prognosis. Although
anti-HER2 therapy is a potential treatment option for HER2-positive SDC, other potential …

Purpose: Previous evaluation of HER2 overexpression in salivary gland cancers indicated
an incidence varying between 7 and 56%, with no clear difference among three …

Objective Salivary duct carcinoma (SDC) overexpresses Human Epidermal growth factor
Receptor 2 (HER2) in 29–46% of cases, favoring anti-HER2 therapy. Here, we present the …